These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19252248)

  • 1. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
    Nakamura T
    Clin Calcium; 2009 Mar; 19(3):381-6. PubMed ID: 19252248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-RANKL antibody for the treatment of rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
    Sugimoto T
    Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
    Tanaka Y
    Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2007 Nov; 17(11):1762-8. PubMed ID: 17982198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoporosis and RANKL signal].
    Nakamura M; Udagawa N
    Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RANKL as a target molecule for treatment of joint destruction].
    Tanaka S
    Clin Calcium; 2007 Apr; 17(4):586-92. PubMed ID: 17404489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis treatment by anti-RANKL antibody].
    Sugimoto T
    Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
    Deodhar A; Dore RK; Mandel D; Schechtman J; Shergy W; Trapp R; Ory PA; Peterfy CG; Fuerst T; Wang H; Zhou L; Tsuji W; Newmark R
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):569-74. PubMed ID: 20391513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis].
    Kotake S; Yago T; Nanke Y
    Nihon Rinsho; 2009 May; 67(5):996-1002. PubMed ID: 19432123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in bone biology and new treatments for bone loss.
    Gallagher JC
    Maturitas; 2008 May; 60(1):65-9. PubMed ID: 18555623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Animal models for bone and joint disease. RANKL-injected bone loss model].
    Yasuda H
    Clin Calcium; 2011 Feb; 21(2):197-208. PubMed ID: 21289416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
    Nakayamada S; Tanaka Y
    Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathologic condition of osteoporosis in rheumatoid arthritis].
    Suwa A; Saito E; Wakabayashi T; Suzuki Y
    Clin Calcium; 2007 Aug; 17(8):1262-6. PubMed ID: 17660625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of joint destruction by osteoclast-targeting therapy in search of new tools, such as OPG or cathepsin K inhibitor].
    Kadono Y; Tanaka S
    Clin Calcium; 2009 Mar; 19(3):387-93. PubMed ID: 19252249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice.
    Ishizuka Y; Moriwaki S; Kawahara-Hanaoka M; Uemura Y; Serizawa I; Miyauchi M; Shibata S; Kanaya T; Takata T; Taniguchi N; Niida S
    J Bone Miner Res; 2007 Dec; 22(12):1933-42. PubMed ID: 17680722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
    Tanaka Y
    Clin Calcium; 2010 Oct; 20(10):1545-52. PubMed ID: 20890038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.